Department of Surgery II, Faculty of Medicine, University of Miyazaki, Kiyotake, Miyazaki, Japan
Department of Surgery II, Faculty of Medicine, University of Miyazaki, Kiyotake, Miyazaki, Japan.
Anticancer Res. 2014 Jun;34(6):3137-40.
Our previous study showed the prognostic impact of preoperative Glasgow prognostic score (GPS) in patients who underwent resection for non-small cell lung cancer (NSCLC). In the present study, the relationship between postoperative GPS and prognosis was also examined in patients with NSCLC with preoperative GPS 1 or 2.
Three hundred and twelve consecutive patients resected for NSCLC with a follow-up period of more than five years were enrolled. The GPS was calculated as follows: patients with elevated C-reactive protein level (>1.0 mg/dl) and hypoalbuminemia (<3.5 g/dl) were assigned to GPS 2. Patients with one or no abnormal value were assigned to GPS 1 or GPS 0.
Study patients were allocated as follows: 264 (84.62%) to GPS 0; 31 (9.94%) to GPS 1; and 17 (5.45%) to GPS 2. The prognosis of the patients with preoperative GPS 2 was significantly poorer. Postoperative GPS was also examined for 48 patients with preoperative GPS 1 or 2. In 30/48 patients, postoperative GPS was improved to GPS 0, however, the postoperative GPS of the remaining 18 patients did not change to GPS 0. The 5-year survival of patients with postoperative GPS 0 and 1-2 were 73.02% and 11.11%, respectively.
Preoperative GPS may be useful for postoperative prognosis of patients with NSCLC. Furthermore, persistently high GPS after surgery indicates poor prognosis in patients with NSCLC.
我们之前的研究表明，术前格拉斯哥预后评分（GPS）对接受非小细胞肺癌（NSCLC）切除术的患者具有预后影响。在本研究中，我们还检查了术前 GPS 为 1 或 2 的 NSCLC 患者术后 GPS 与预后的关系。
纳入了 312 例接受 NSCLC 切除术且随访时间超过 5 年的连续患者。GPS 的计算方法如下：C 反应蛋白水平升高（>1.0mg/dl）和低白蛋白血症（<3.5g/dl）的患者被分配为 GPS 2。有一个或没有异常值的患者被分配为 GPS 1 或 GPS 0。
研究患者的分配情况如下：264 例（84.62%）为 GPS 0；31 例（9.94%）为 GPS 1；17 例（5.45%）为 GPS 2。术前 GPS 2 的患者预后明显较差。还对 48 例术前 GPS 为 1 或 2 的患者进行了术后 GPS 检查。在 48 例患者中的 30 例中，术后 GPS 改善为 GPS 0，但其余 18 例患者的术后 GPS 未改善为 GPS 0。术后 GPS 0 和 1-2 的患者 5 年生存率分别为 73.02%和 11.11%。
术前 GPS 可能对 NSCLC 患者的术后预后有用。此外，术后 GPS 持续升高表明 NSCLC 患者预后不良。
